TheraCryf to Host Investor Webinar on Ox-1 Program

An update from Evgen Pharma ( (GB:TCF) ) is now available.

TheraCryf plc announced an upcoming investor webinar focused on its Ox-1 addiction program, scheduled for June 11, 2025. The session, led by the company’s CBO and a consulting neuroscientist, aims to provide an in-depth look at the program and is open to all existing and potential shareholders. This initiative reflects TheraCryf’s strategy to engage stakeholders and potentially strengthen its market position in neuropsychiatry and oncology.

Spark’s Take on GB:TCF Stock

According to Spark, TipRanks’ AI Analyst, GB:TCF is a Neutral.

Evgen Pharma’s overall stock score of 49 reflects ongoing financial and operational challenges, including declining revenues and losses. While the technical analysis shows mixed momentum, recent corporate events provide a positive outlook with strategic initiatives aimed at improving financial stability and advancing key drug development programs.

To see Spark’s full report on GB:TCF stock, click here.

More about Evgen Pharma

TheraCryf plc is a clinical stage drug development company focusing on brain disorders, including addiction, anxiety, fatigue, narcolepsy, glioblastoma, and neurodevelopmental disorders. The company aims to generate compelling data sets for preclinical and clinical proof of concept, partnering with mid-size to large pharmaceutical companies for larger trials and commercialization. TheraCryf collaborates with major universities and hospitals and has industry partnerships, including with Stalicla SA.

Average Trading Volume: 4,729,076

Technical Sentiment Signal: Sell

Current Market Cap: £5.69M

See more data about TCF stock on TipRanks’ Stock Analysis page.